FindTrial
Sign In

Phase II clinical study on combination of oxaliplatin (L-OHP) and S-1 in advanced / recurrent gastric cancer untreated with chemotherapy

Phase II clinical study on combination of oxaliplatin (L-OHP) and S-1 in advanced / recurrent gastric cancer untreated with chemotherapy

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220365
Enrollment
Unknown
Registered
2007-03-22
Start date
2007-03-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

investigational material(s) Generic name etc : Oxaliplatin|Tegafur-Gimeracil-Oteracil potassium capsule INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage

Sponsors

Yakult Honsha Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Gastric cancer confirmed by histological diagnosis or cytologic diagnosis - Unresectable advanced / recurrent gastric cancer - Age of 20 years or older - Not pretreated with chemotherapy drugs, immunotherapeutic drugs, or radiation therapy - ECOG Performance Status 0 to 2

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Response Rate—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026